Diabetes arises because of insufficient beta cells that produce insulin in the pancreas. In type 1, the cells die because of an attack on the immune system. In type 2, the body becomes resistant to insulin and the cells try to compensate by producing more, which doesn’t work.
Researchers, led by Rupangi Vasavada at Mount Sinai Hospital in New York have found a link between bone formation and the expansion of pancreatic beta cells.
Vasavada’s team is analyzing how Denosumab and a protein that is bone-derived called osteoprotegerin (OPG) regulate the growth and activity of beta cells.
The team is now looking to begin clinical trials in patients who are being treated for diabetes with denosumab, and treat them for osteoporosis.